Butterfly Skin Therapy Pipeline Primed For Transformation

As Amryt's Oleogel-S10 Gets Priority Review

03 Jun 2021

No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.

The odds of having an approved therapy for epidermolysis bullosa (EB) by the end of 2021 have improved with the news that US regulators have fast-tracked Amryt Pharma's Oleogel-S10 but gene therapies are also coming through the pipeline that could tackle the underlying cause of the rare genetic disorder that causes skin to be extremely fragile.

First up, Ireland's Amryt, which is listed on the NASDAQ and London's AIM market, has revealed that the US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

06 Jun 2025

• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.